A Biology Modality MCP review of CCR10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF11A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF25 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF19 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF18 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF13C protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF12A protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

A Biology Modality MCP review of TNFRSF10D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.

Renibus Therapeutics, Inc BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.

Restem Group, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.

RenBio, Inc. BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.

Resolvyx Pharmaceuticals BD opportunity scan covering pipeline ownership, development stage, evidence package, IP risk, deal precedent and outreach rationale using PatSnap MCP.